Assessing uptake of the macular degeneration core outcome set in clinical trials: a cross-sectional study

Eli Oldham, R Hunter Hall, Garrett Jones, Jay Modi, Shaelyn Ward, Trevor Magee, Kyle Fitzgerald, Kimberly Magana, Griffin Hughes, Alicia Ito Ford, Matthew Vassar · 2025

Read Assessing uptake of the macular degeneration core outcome set in clinical trials: a cross-sectional study by Eli Oldham, R Hunter Hall, Garrett Jones, Jay Modi, Shaelyn Ward, Trevor Magee, Kyle Fitzgerald, Kimberly Magana, Griffin Hughes, Alicia Ito Ford, Matthew Vassar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742102.txt.

Description

Eli Oldham leads a team of eleven in a 2025 study on whether eye trials use the agreed outcome set for macular degeneration. A core outcome set lists the measures every trial of a disease should report, so results can be compared. Uptake of the eye set had not been gauged.

The team pulled more than two thousand registered trials from a public registry and kept 159 that fit their rules. They then checked how many reported the core measures, and whether use rose after the set came out. A time-series read found no clear jump. Traits of the trials were also weighed against how fully they used the set.

Catalog record

CREATOREli Oldham, R Hunter Hall, Garrett Jones, Jay Modi, Shaelyn Ward, Trevor Magee, Kyle Fitzgerald, Kimberly Magana, Griffin Hughes, Alicia Ito Ford, Matthew Vassar
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12742102

Browse the full library · About the Tower of Babel